Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) and other ASCVD risk factors were measured at baseline (1996-1998) in the biracial Atherosclerosis Risk in Communities study; participants without prevalent ASCVD (coronary heart disease or stroke) were monitored ∼15 years for incident ASCVD events.
|
30685442 |
2019 |
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Even if proprotein convertase subtilisin/kexin type 9 inhibitors have replaced lipoprotein apheresis in many patients, lipoprotein apheresis still is an important option in homozygous familial hypercholesterolemia, progressive atherosclerosis or when removal of lipoprotein(a) is indicated.
|
31782556 |
2019 |
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The European Atherosclerosis Society recommends screening for elevated lipoprotein(a) levels in high-risk patients.
|
31111240 |
2019 |
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, mice with inherited deficiency in LPA receptor signaling are protected from experimental atherosclerosis.
|
31533471 |
2019 |
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The use of transgenic and gene knockout animals, gene manipulated cells, pharmacological LPA receptor agonists and antagonists have provided many insights into the biological significance of LPA and individual LPA receptors in the progression of atherosclerosis and vascular diseases.
|
31472182 |
2019 |
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evaluating the Potential Association Between Lipoprotein(a) and Atherosclerosis (from the Mediators of Atherosclerosis Among South Asians Living in America Cohort).
|
30626499 |
2019 |
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A considerable body of data from genetic and epidemiological studies strongly support a causal relationship between high lipoprotein(a) [Lp(a)] levels, and the development of atherosclerosis and cardiovascular disease.
|
31350625 |
2019 |
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The conventional model of atherosclerosis presumes that the mass of cholesterol within very low-density lipoprotein particles, low-density lipoprotein particles, chylomicron, and lipoprotein (a) particles in plasma is the principal determinant of the mass of cholesterol that will be deposited within the arterial wall and will drive atherogenesis.
|
31642874 |
2019 |
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Nontraditional cardiovascular risk factors such as lipoprotein(a) (Lp(a)), the genetic polymorphisms of apolipoprotein(a), apolipoprotein E (ApoE), and apolipoprotein B (ApoB) increase the prevalence of atherosclerosis in end-stage renal disease (ESRD) through quantitative and qualitative alterations.
|
31119518 |
2019 |
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Objective- Lp(a) [lipoprotein(a)] is a well-described risk factor for atherosclerosis, but Lp(a)-associated risk may vary by race/ethnicity.
|
30727753 |
2019 |
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lipoprotein (a) (Lp(a)) is a risk factor for atherosclerosis but its role in IRD with accompanying coronary artery disease (CAD) is still unclear.
|
31079089 |
2019 |
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We examined the association of apolipoprotein B (ApoB), small-dense low-density lipoprotein cholesterol (sdLDL-C), lipoprotein (a) (Lp[a]), and lipoprotein-associated phospholipase A<sub>2</sub> (LpPLA<sub>2</sub>) activity with 15-year change in Delayed Word Recall Test, Digit Symbol Substitution Test (DSST), Word Fluency Test (WFT), and overall summary score in 9,350 participants in the Atherosclerosis Risk in Communities study.
|
31043469 |
2019 |
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis.
|
30586750 |
2019 |
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
While most work has focused on LDL, oxidation of which has long been associated with pro-inflammatory responses and atherosclerosis, some studies on HDL, VLDL and Lipoprotein(a) have also been reported.
|
30579928 |
2019 |
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review summarizes recent findings of the roles played by ATX, LPA and LPA receptors (LPARs) in atherosclerosis and calcific aortic valve disease.
|
30928673 |
2019 |
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Apo A-I (Apolipoprotein A-I) Vascular Gene Therapy Provides Durable Protection Against Atherosclerosis in Hyperlipidemic Rabbits.
|
29122817 |
2018 |
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) accelerated the progression of atherosclerosis in patients with end-stage renal disease.
|
30071823 |
2018 |
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Finally, we find that LPA risk genotypes confer greater relative risk for incident atherosclerotic cardiovascular diseases compared to directly measured Lp(a), and are significantly associated with measures of subclinical atherosclerosis in African Americans.
|
29973585 |
2018 |
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we performed the first exploratory analysis of PLPP3, LPA, and LPA receptors (LPARs 1-6) in human atherosclerosis.
|
30003117 |
2018 |
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast, atherosclerosis in heterozygous FH differs in several respects from that of homozygotes, notably the lack of aortic root involvement and in its multifactorial aetiology, with raised LDL cholesterol, male gender, low HDL cholesterol and raised lipoprotein (a) all contributing to its clinical expression.
|
30064057 |
2018 |
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This may include measurement of inflammatory markers, subclinical indicators of atherosclerosis (e.g., coronary artery calcium and ankle brachial index), urinary albumin/creatinine ratio, and the level of lipoprotein (a).
|
29556802 |
2018 |
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lipoprotein(a) Lp(a) is a cholesterol-rich, LDL-like particle that is independently associated with an increased risk for ischemic heart disease, atherosclerosis, thrombosis, and stroke.
|
28608522 |
2018 |
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We previously demonstrated an association between lipoprotein (a) [Lp(a)] levels and atherosclerosis in human immunodeficiency virus (HIV)-seropositive women.
|
30012717 |
2018 |
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In these patients, low adiponectin and high lipoprotein(a) levels are found which are known to be associated with endothelial dysfunction, atherosclerosis and coronary artery disease.
|
27007665 |
2018 |
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipid levels were measured and a proteomic approach was used to quantify proteins in the livers of mice with an elevated low-density lipoprotein (LDL) and the presence of lipoprotein(a) [Lp(a)] but no atherosclerosis.
|
30596094 |
2018 |